Startups channel feed

Ex­clu­sive: Backed by for­mer Google CEO’s VC, a Col­orado biotech hatch­es plat­form to evolve de­graders

Last year
Financing
R&D

Ex­clu­sive: Backed by Il­lu­mi­na, Bro­ken String Bio­sciences rais­es $15M to find off-tar­get gene ed­its

Last year
Financing
Cell/Gene Tx

Lyn­dra lays off 23% of work­ers, to out­source man­u­fac­tur­ing as it ap­proach­es piv­otal read­out next month

Last year
People

Neumo­ra, Rayze­Bio ride on­to Nas­daq in IPO dou­ble­head­er, breath­ing life in­to fall list­ings

Last year
Financing

Gene ther­a­py biotech Alveo­Gene launch­es with lentivi­ral plat­form for res­pi­ra­to­ry dis­eases

Last year
R&D
Cell/Gene Tx

Ex­clu­sive: Phar­ma­cy ad­her­ence start­up Sem­pre Health rais­es $20M

Last year
Financing
Health Tech

Ex­clu­sive: Two ex-Re­cur­sion lead­ers start Noetik in a bid to fix the bro­ken fun­nel in can­cer drug re­search

Last year
Financing

Ex­clu­sive: Dana­her’s ven­ture arm backs cell ther­a­py man­u­fac­tur­ing start­up co-found­ed by Carl June

Last year
Cell/Gene Tx
Manufacturing

Ex­clu­sive: Khosla Ven­tures leads seed round in mR­NA biotech look­ing to re­verse ag­ing by length­en­ing telom­eres

Last year
Financing

Stars align as ex-True North team nabs an­oth­er $90M to build out biotech con­stel­la­tion

Last year
Financing

Can­cer care start­up Thyme Care rais­es $60M, beat­ing the odds of rais­ing a Se­ries B dur­ing dig­i­tal health’s fund­ing slow­down

Last year
Financing
Health Tech

Ex­clu­sive: Stem cell sci­en­tist and bit.bio founder launch­es new start­up with goal of ex­tend­ing healthspan by 20 years

Last year
Financing

Scoop: Metageno­mi is prepar­ing for an IPO this fall, in what could jump­start a wave of pub­lic of­fer­ings

Last year
Financing

Lil­ly qui­et­ly com­pletes pur­chase of Pad­cev com­peti­tor, es­ti­mat­ed at near­ly half a bil­lion dol­lars

Last year
Deals
Pharma

Epi­genic Ther­a­peu­tics en­ters crowd­ed glob­al gene ther­a­py mar­ket with $32M Se­ries A

Last year
Financing

Cell ther­a­py start­up Notch Ther­a­peu­tics clos­es one of three sites

Last year
People
Cell/Gene Tx

i2o Ther­a­peu­tics clos­es $46M Se­ries A, names Kurt Graves as CEO and ac­quires Intar­cia’s twice-re­ject­ed di­a­betes as­set

Last year
People
Financing

For­mer Schrödinger ex­ec launch­es RA Cap­i­tal-backed start­up for AI drug dis­cov­ery

Last year
Financing

Neu­mora's big neu­ro­science plans head to­ward the Nas­daq in sec­ond PhI­II biotech IPO pitch in 24 hours

Last year
Financing

Ra­dio­phar­ma­ceu­ti­cals start­up Rayze­Bio sub­mits IPO pitch, fore­shad­ow­ing ex­pect­ed post-La­bor Day bump in biotech list­ings

Last year
Financing

Fore scores $75M Se­ries D, tees up new lead­er­ship with ex-El­e­va­tion CEO Shawn Le­land at the helm — for now

Last year
Financing

Rap­port bags $150M Se­ries B just five months af­ter nine-fig­ure launch for epilep­sy, psy­chi­a­try tri­als

Last year
Financing

Skye ac­quires Bird Rock Bio, weeks af­ter No­vo Nordisk says it will buy a CB1 de­vel­op­er

Last year
Financing
Deals

ARCH's lat­est biotech, tar­get­ing can­cer re­cur­rence, emerges from Co­lum­bia pro­fes­sor who worked on Biden's moon­shot

Last year
Financing
First page Previous page 25262728293031 Next page Last page
A service from the Financial Times